Evidence map›Paper›PMID 42848111›Full record

ReviewEJNMMI radiopharmacy and chemistry2026

Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Sarah Spreckelmeyer, Jean DaSilva, Clemens Decristoforo, Robert H Mach, Jan Passchier, Giuseppe Carlucci, Adriano Duatti, Bart T Cornelissen, Antonia Denkova, Jeroen Hendrikx and 13 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Sarah SpreckelmeyerDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. sarah.spreckelmeyer@charite.de.ORCID http://orcid.org/0000-0003-1348-0309
Jean DaSilvaUniversité de Montréal, Montreal, Canada.
Clemens DecristoforoInnsbruck Medical University, Innsbruck, Austria.
Robert H MachUniversity of Pennsylvania, Philadelphia, USA.
Jan PasschierCITRAS Global Ltd., London, UK.
Giuseppe CarlucciJubilant Radiopharma, Kirkland, Canada.
Adriano DuattiUniversity of Ferrara, Ferrara, Italy.
Bart T CornelissenUniversity Medical Center Groningen, Groningen, The Netherlands.
Antonia DenkovaDelft University of Technology, Delft, The Netherlands.
Jeroen HendrikxThe Netherlands Cancer Institute, Amsterdam, The Netherlands.
Yann SeimbilleErasmus Medical Center, Rotterdam, The Netherlands.
Xing YangPeking University First Hospital, Beijing, China.
Hongmei JiaBeijing Normal University, Beijing, China.
Ming-Rong ZhangNational Institutes for Quantum Science and Technology, Chiba, Japan.
Lars PerkRadboud University Medical Center, Nijmegen, The Netherlands.
Peter CaravanMassachusetts General Hospital, Boston, USA.
Jan Rijn ZeevaartNECSA, NuMeRI NPC, University of Pretoria, Pretoria, Pretoria, Pretoria, South Africa.
Julien LeenhardtUniversité Grenoble Alpes, Saint-Martin-d'Hères, France.
Juan PellicoInstitut de Ciència de Materials de Barcelona, Cerdanyola des Vallès, Barcelona, Spain.
Mohammed Hussain Al-QahtaniCyclotron & Radiopharmaceutical Department, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Zhen ChengShanghai Institute of Materia Medica, Chinese Academy of Sciences, Beijing, Pudong, China.
Tamer SakrEgyptian Atomic Energy Authority, Cairo, Egypt.
Min YangJiangsu Institute of Nuclear Medicine, Wuxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development and application of radiopharmaceuticals. MAIN BODY: This selection of highlights provides commentary on 23 different topics selected by each co-authoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry, proof-of-concepts, preclinical and early clinical studies using novel radiopharmaceuticals.

conclusionTrends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field in many aspects.

Indexed as

Highlight articlesNuclear medicineRadiochemistryRadiopharmaceutical sciencesRadiopharmacy

Identifiers

PMID42848111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.